Beam Therapeutics Inc.

NASDAQ:BEAM

23.31 (USD) • At close September 6, 2024
Bedrijfsnaam Beam Therapeutics Inc.
Symbool BEAM
Munteenheid USD
Prijs 23.31
Beurswaarde 1,921,107,636
Dividendpercentage 0%
52-weken bereik 16.95 - 49.5
Industrie Biotechnology
Sector Healthcare
CEO Mr. John M. Evans M.B.A.
Website https://www.beamtx.com

An error occurred while fetching data.

Over Beam Therapeutics Inc.

Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor

Vergelijkbare Aandelen

PTC Therapeutics, Inc. logo

PTC Therapeutics, Inc.

PTCT

31.54 USD

Tilray Brands, Inc. logo

Tilray Brands, Inc.

TLRY

1.62 USD

Arvinas, Inc. logo

Arvinas, Inc.

ARVN

24.4 USD

EQRx, Inc. logo

EQRx, Inc.

EQRX

2.34 USD

Iovance Biotherapeutics, Inc. logo

Iovance Biotherapeutics, Inc.

IOVA

10.01 USD

Corcept Therapeutics Incorporated logo

Corcept Therapeutics Incorporated

CORT

34.38 USD

Insmed Incorporated logo

Insmed Incorporated

INSM

71.04 USD

AbCellera Biologics Inc. logo

AbCellera Biologics Inc.

ABCL

2.39 USD

Fate Therapeutics, Inc. logo

Fate Therapeutics, Inc.

FATE

3.39 USD

Canopy Growth Corporation logo

Canopy Growth Corporation

CGC

4.48 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)